Source comparison
Melanotan-1 vs PT-141 — Mechanism & Use Differences
A 2019 Phase 3 trial published in Obstetrics & Gynecology found that bremelanotide (PT-141) improved sexual desire scores by 1.2 points on the Female Sexual Function Index compared to placebo. A clinically meaningful change driven by activation of melanocortin
This comparison does not assign a generated winner or score.
- A 2019 Phase 3 trial published in Obstetrics & Gynecology found that bremelanotide (PT-141) improved sexual desire scores by 1.2 points on the Female Sexual Function Index compared to placebo. A clinically meaningful change driven by activation of melanocortin-4 receptors in the hypothalamus. That same melanocortin pathway also controls skin pigmentation through MC1R, which is where Melanotan-1 operates. The peptides share a structural ancestor but target completely different receptor subtypes.
- We've worked with research facilities studying both compounds across dermatology and neuroendocrinology. The gap between understanding their shared lineage and recognising their functional divergence is where most confusion lives.
- What's the difference between Melanotan-1 and PT-141?
- Melanotan-1 (afamelanotide) is a synthetic α-MSH analogue that binds primarily to melanocortin-1 receptors (MC1R) on melanocytes, triggering eumelanin synthesis and skin darkening without UV exposure. PT-141 (bremelanotide) is a cyclic heptapeptide that selectively activates melanocortin-4 receptors (MC4R) in the hypothalamus, modulating sexual arousal and desire through dopaminergic pathways. Both are melanocortin receptor agonists, but receptor selectivity determines their physiological effects. One produces pigmentation, the other modulates libido.
- The difference between Melanotan-1 and PT-141 isn't dosage or administration route. It's receptor affinity. Melanotan-1 has high selectivity for MC1R (the receptor that controls melanin production in skin cells), while PT-141 preferentially binds MC4R (the receptor that regulates sexual motivation in the central nervous system). This receptor divergence means the peptides cannot substitute for one another despite originating from the same parent molecule, Melanotan-II. One triggers a peripheral dermatological response; the other activates a central neurological pathway. This article covers their distinct mechanisms, approved clinical uses, research applications, and why conflating them creates both safety and efficacy problems.